ADMA Biologics 15min chart shows Bollinger Bands narrowing, KDJ death cross.

ADMA Biologics's 15-minute chart has recently exhibited Bollinger Bands Narrowing, coupled with a KDJ Death Cross on September 22, 2025, at 14:00. This suggests that the magnitude of stock price fluctuations is diminishing, and the momentum of the stock is shifting towards a downward trend, potentially leading to further decreases in value.

Adma Biologics (ADMA) stock experienced a notable decline during the recent trading session, closing at $15.30 with a -5.03% change from the previous day. This drop lagged behind the broader market's performance, with the S&P 500, Dow, and Nasdaq posting gains of 0.47%, 0.11%, and 0.94%, respectively Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note^[1].

Over the past month, ADMA's stock has fallen by 5.18%, underperforming the Medical sector's 5.49% gain and the S&P 500's 2.32% increase. Analysts expect the company to report earnings of $0.16 per share for the upcoming quarter, marking a 6.67% year-over-year growth. Additionally, revenue is projected to reach $130.1 million, up 8.56% from the prior year Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note^[1].

For the full fiscal year, Zacks Consensus Estimates project earnings of $0.57 per share and revenue of $506.7 million, representing growth of +16.33% and +18.82%, respectively, from the previous year. Despite these positive projections, ADMA's stock is currently trading at a Forward P/E ratio of 28.26, which is higher than the industry average of 19.79 Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note^[1].

The Medical - Biomedical and Genetics industry, to which ADMA belongs, has a Zacks Industry Rank of 95, placing it in the top 39% of all industries. However, the company's stock has recently exhibited technical indicators suggesting a downward trend. Specifically, the 15-minute chart of ADMA's stock shows Bollinger Bands narrowing and a KDJ Death Cross on September 22, 2025, at 14:00, indicating diminishing price fluctuations and a shift in momentum towards a downward trend Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note^[1].

Investors should closely monitor ADMA's financial results and any changes in analyst estimates. Positive revisions could signal optimism about the business outlook and potentially influence near-term share price momentum. The Zacks Rank system, which considers these estimate changes, currently rates ADMA as a "Hold" (Zacks Rank #3) Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note^[1].